|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trio coherent states显示文摘 | An N B Duc T M | 2002 | J Opt B: Quantum Semiclass Opt2002，4，： | 1 |
| 2 | A New Format for 5- axis Tool Path Computation Using Bspline Curves显示文摘 | Langeron J M Duc E Lartigue C | 2004 | CAD Computer Aided Design2004，36，12： | 1 |
| 3 | Human glioma cells transformed by IGF-1 triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma显示文摘 | Ly A Duc H T Kalamarides M | 2001 | Mol Pathol2001，54，4： | 1 |
| 4 | Ellagic compounds from Diplopanax stachyanthus 显示文摘 | Duc D K Sung T V Angela M C | 1990 | Phytochemistry1990，29，1： | 1 |
| 5 | Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery显示文摘 | DUC L H HONG H A CUTTING S M | 2003 | Vaccine2003，21，2730： | 1 |
| 6 | Characterization of Bacillus Probiotics Available for Human Use显示文摘 | Duc L H Hong H A Barbosa T M | 2004 | Appl Environ Microbiol2004，70，4： | 1 |
| 7 | Ellagic compounds from Diplopanax stachyanthus 显示文摘 | Duc D K Sung T V Angela M C | 1990 | Phytochemistry1990，29，1： | 1 |
| 8 | Characterization of Bacillus probiotics available for human use显示文摘 | DUC L H HONG H A BARBOSA T M | 2004 | Appl Environ Microbiol2004，70，4： | 1 |
| 9 | Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner显示文摘 | MAURIELLO E M F DUC L H ISTICATO R | 2004 | Vaccine2004，22，910： | 1 |
| 10 | The use of bacterial spore formers as probiotics 显示文摘 | Hong H A Duc L H Cutting S M | 2005 | FEMS Microbiology Reviews2005，29，4： | 1 |
| 11 | Antireflux ureteroileal implantation via a mucosal sulcus显示文摘 | LE DUC A CAMEY M TEILLAC P | 1987 | Ann Urol (Paris)1987，21，1： | 1 |
| 12 | Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography显示文摘 | Weber O M Verhagen A Duc O | 1999 | Magn Reson Imaging1999，17，3： | 1 |
| 13 | Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression 显示文摘 | Klocster R Y M R le Duc Q | 2009 | J Immunol Methods2009，342，12： | 1 |
| 14 | Sorption of selenium anionic species on apatites and iron oxides from aqueous solutions显示文摘 | Duc M Lefevre G Fedoroff M | 2003 | Journal of Environmental Radioactivity2003，，70： | 1 |
| 15 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 16 | Medial collateral ligament injuries:evaluation of mutiple signs prevalence and location of associated bone bruises and assessment with MR imaging显示文摘 | Duc Tran Diane M | 1995 | Radiology1995，194，： | 1 |
| 17 | gyrB as a phylogenetic discriminator for members of the Bacillus anthracis- cereus-thuringiensis group 显示文摘 | LA DUC M T SATOMI M AGATA N | 2004 | J Microbiol Methods2004，56，3： | 1 |
| 18 | Conservative therapy in patients with anterior disc displacement without reduction using common splints:a randomized clinical trial显示文摘 | Schmitter M Zahran M Duc JM | 2005 | J Oral Maxillofac Surg2005，63，9： | 1 |
| 19 | Sim- ultaneous monitoring of volatile selenium and sulfur species from se accumulating plants (wild type and genetically modified)by GC/MS and GC/ICPMS u sing solid-phase microextraction for sample introduc- tion显示文摘 | J Meija M Montes-Bayon D L Ire Duc | 2002 | AnalChem2002，74，： | 1 |
| 20 | The use of bacterial spore formers as probiotics显示文摘 | HONG H A DUC L H CUTTING S M | 2005 | FEMS Microbiol Rev2005，29，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员